Information updates

TGA approval for Pfizer COVID-19 vaccine booster dose in Australia

The Therapeutic Goods Administration (TGA) has approved a booster dose of the Pfizer COVID-19 vaccine for individuals 18 years and older in Australia.

The TGA approval means that the Pfizer COVID-19 vaccine has been found safe and effective to boost protection for individuals aged 18 years and older through a third booster dose provided at least six months after the completion of a COVID-19 vaccine primary course of two doses. The primary course can be of any of the COVID-19 vaccine registered for use in Australia.

People remain fully vaccinated with two doses of TGA approved COVID-19 vaccines and the commencement of booster doses will provide additional protection and peace of mind for Australians.

Subject to final advice provided to the Government by the Australian Technical Advisory Group on Immunisation (ATAGI), it is expected that a general population booster program will commence no later than 8 November with original priority groups, including people in aged care and disability care settings, to be offered the option to receive a booster as a priority.

The Government also expects that Moderna will shortly apply to the TGA for registration of booster doses for their vaccine.

Since 11 October, Australians who are severely immunocompromised have been able to receive a third COVID-19 vaccine dose to boost their protection against COVID-19 to the highest level.

Further information: 

https://www.allergy.org.au/about-ascia/info-updates/third-covid-19-vaccine-shot-recommended-for-people-who-are-severely-immunocompromised

https://www.health.gov.au/ministers/the-hon-greg-hunt-mp/media/tga-approval-for-pfizer-covid-19-vaccine-booster-dose-0

 

Mod ASCIA Member
Donate to AIFA
go to NAS website
ASCIA Member Login
ASCIA Update

Information for the community about allergic diseases, immunodeficiencies and other immune diseases.
See latest edition here...
Join our mailing list:

About ASCIA

ASCIA is the peak professional body of clinical immunology and allergy in Australia and New Zealand
ASCIA promotes and advances the study and knowledge of allergy and other immune diseases

Quick Links

About ASCIA

ASCIA is a registered trademark of the Australasian Society of Clinical Immunology and Allergy. All content is subject to copyright for the Australasian Society of Clinical Immunology and Allergy. Read more...

The content for the website is developed and approved by ASCIA Committee and ASCIA Working Party Members. Read more...

Disclaimer I Privacy

The ASCIA website is intended for use by ASCIA members, health professionals and the general public. The content provided is for education, communication and information purposes only and is not intended to replace or constitute medical advice or treatments. Read more...

ASCIA respects your privacy. Read our privacy policy here...

Sponsors | Advertising

ASCIA does not endorse products from sponsoring organisations, nor is it influenced by sponsoring organisations with regard to the content of education programs and websites. 

The ASCIA website does not accept advertising. Any link to a third-party website does not imply any endorsement by ASCIA.

Accreditiation

healthdirect

This website is certified by Health On the Net Foundation. Click to verify. This site complies with the HONcode standard for trustworthy health information: verify here.